Fluvoxamine vs Tianeptine

Fluvoxamine wins for: neuroinflammatory conditions, cognitive resilience, SSRIs users sensitive to sexual side effects, and research use favoring sigma-1 modulation at sub-psychiatric doses. Side effect and dependence profile is well understood and manageable, with minimal abuse potential.

Tianeptine wins for: rapid mood elevation, acute anxiolysis, social fluidity, and post-cycle or harsh-diet mood stabilization — provided strict opioid-style protocols are followed. Onset and offset are both much faster, with a unique absence of sexual blunting, but carries real opioid-agonist dependence risk at high or frequent doses.

Pick Fluvoxamine if:

• Research focus is on sigma-1 receptor agonism or neuroprotection, especially in post-viral or neuroinflammatory models.
• Protocol targets OCD, intrusive thoughts, or serotonin-mediated symptoms while avoiding traditional SSRI sexual side effects.
• Stacks call for an SSRI with added anti-inflammatory action (FIASMA effect).
• Long-COVID, cognitive fog, or mitochondrial stress are primary endpoints.
• CYP inhibition is not a major concern for the overall protocol.

Pick Tianeptine if:

• The protocol requires fast-acting, opioid-mediated mood lift or anxiolysis, especially around social events or acute stressors.
• The research aims for post-cycle mood support in models where typical serotonergic agents are ineffective or counterproductive.
• Minimizing sexual or emotional blunting is a major experimental goal.
• Highly intermittent or single-use protocols (e.g., pre-shoot, pre-event) are acceptable and the risk of dependence can be strictly managed.
• Tolerance build-up and opioid-like withdrawal risks can be tightly controlled and monitored within the protocol.